You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Reaping the Rewards of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Diabetes Care: Who/Why/When/How?

  • Authors: Melanie Davies, MD; Juan P. Frias, MD; Carol H. Wysham, MD
  • CPD Released: 1/26/2022
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 1/26/2023
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US and non-UK diabetologists and endocrinologists, primary care physicians, and cardiologists.

The goal of this activity is to illustrate the benefits of glucagon-like peptide-1 (GLP-1) receptor agonist (RA) therapy for patients with type 2 diabetes (T2D) and provide practical advice for their safe and appropriate use in clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Guideline recommendations for the early preferred use of GLP-1 RAs in certain patients with T2D
    • Cardiovascular (CV) benefits of long-acting GLP-1 RAs
  • Have greater competence related to
    • Appropriate Initiation of GLP-1 RA therapy


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

-


Faculty

  • Melanie Davies, MD

    Professor of Diabetes Medicine
    University of Leicester
    University Hospitals of Leicester NHS Trust
    Leicester Diabetes Centre
    Leicester, United Kingdom

    Disclosures

    Disclosure: Melanie Davies, MD, has the following relevant financial relationships:
    Advisor or consultant for: Boehringer Ingelheim; Lexicon; Lilly; Novo Nordisk; Sanofi
    Speaker or a member of a speakers bureau for: Actoverco Pharmaceuticals; AstraZeneca; Boehringer Ingelheim; CCL Pharmaceuticals; Lilly; Napp Pharmaceuticals; Novo Nordisk; Pfizer; Sanofi
    Grants for clinical research from: AstraZeneca; Boehringer Ingelheim; Janssen; Novo Nordisk; Sanofi

  • Juan P. Frias, MD

    Medical Director and Principal Investigator
    National Research Institute
    Los Angeles, California
    Assistant Clinical Professor of Medicine
    Division of Endocrinology
    University of California San Diego
    San Diego, California, United States

    Disclosures

    Disclosure: Juan P. Frias, MD, has the following relevant financial relationships:
    Advisor or consultant for: Akero; Altimmune; Axcella Health; Boehringer Ingelheim; Carmot; Coherus Therapeutics; Echosens; 89bio; Eli Lilly; Gilead; Intercept; Merck; Novo Nordisk; Pfizer; Sanofi
    Speaker or a member of a speakers bureau for: Eli Lilly; Merck; Sanofi
    Grants for clinical research from: Akero; AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly; Intercept; Janssen; Madrigal; Metacrine; Merck; NorthSea Therapeutics; Novartis; Novo Nordisk; Oramed; Pfizer; Poxil; Sanofi; Theracos

  • Carol H. Wysham, MD

    Clinical Professor of Medicine
    University of Washington School of Medicine
    Rockwood/MultiCare Center for Diabetes and Endocrinology
    Spokane, Washington, United States

    Disclosures

    Disclosure: Carol H. Wysham, MD, has the following relevant financial relationships:
    Advisor or consultant for: Abbott; Novo Nordisk; Sanofi
    Speaker or a member of a speakers bureau for: AstraZeneca; Boehringer Ingelheim; Eli Lilly; Janssen; Novo Nordisk; Sanofi
    Grants for clinical research from: Abbott; Corcept; Eli Lilly; Gilead; Milan Laboratories; Novo Nordisk

Editors

  • Marcel Meijer, PhD

    Senior Director, Content Development WebMD Global, LLC

    Disclosures

    Disclosure: Marcel Meijer, PhD, has disclosed no relevant financial relationships.

  • Grace O'Malley, PhD

    Associate Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Grace O'Malley, PhD, has disclosed no relevant financial relationships.

Content Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Susan L. Smith, MN, PhD, has disclosed no relevant financial relationships. 

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Reaping the Rewards of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Diabetes Care: Who/Why/When/How?

Authors: Melanie Davies, MD; Juan P. Frias, MD; Carol H. Wysham, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 1/26/2022

Valid for credit through: 1/26/2023

processing....

Select Any Chapter to Begin

Are you confident in determining which patients with type 2 diabetes would benefit from a GLP-1 RA? Do you know when, and how, to initiate this treatment? Are you up-to-date on the multifactorial effects of GLP-1 RAs, and the latest treatment guidelines? Join this micro to find out more

  • Print